Literature DB >> 12642745

Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study.

Henrik Toft Sørensen1, Lene Mellemkjaer, Peter Jepsen, Ane Marie Thulstrup, John Baron, Jørgen H Olsen, Hendrik Vilstrup.   

Abstract

GOALS: To examine the risk of cancer in patients with fatty liver.
BACKGROUND: The relation between liver disease, including fatty liver, and cancer risk is poorly understood. STUDY: Using the population-based National Registry of Patients, we examined the incidence of cancer in 7,326 patients discharged with a diagnosis of fatty liver from a Danish hospital during 1977-1993. Patients with a prior diagnosis of liver cirrhosis were excluded. We identified cancers through the Danish Cancer Registry. The expected number of cancers was estimated from national age-, sex-, and site-specific incidence rates.
RESULTS: Overall, 523 cancers were diagnosed during 47,594 person-years of follow-up, yielding a 1.7-fold increased risk (95% confidence interval, 1.6-1.9) compared with the Danish general population. The risk of primary liver cancer was markedly elevated in patients with alcoholic as well as nonalcoholic fatty liver with a standardized incidence ratio of 9.5 (95% confidence interval, 5.7-14.8) and 4.4 (95% confidence interval, 1.2-11.4), respectively. Patients with alcoholic fatty liver also had substantially increased risks of several types of cancer associated with alcohol and tobacco use (cancers of the lung, pharynx, larynx, esophagus, and stomach) and a moderately increased risk for cancers of the colon and breast. Among patients with nonalcoholic fatty liver, an increased risk of some alcohol- and tobacco-related cancers was seen, and there was also an increased risk of colon and pancreas cancer.
CONCLUSIONS: Patients discharged with a diagnosis of fatty liver have an increased risk of cancer, in particular liver cancer, most prominently among patients with alcoholic fatty liver.

Entities:  

Mesh:

Year:  2003        PMID: 12642745     DOI: 10.1097/00004836-200304000-00015

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  31 in total

Review 1.  Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 2.  Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.

Authors:  Sebastian Weis; Annegret Franke; Thomas Berg; Joachim Mössner; Wolfgang E Fleig; Konrad Schoppmeyer
Journal:  Cochrane Database Syst Rev       Date:  2015-01-26

Review 3.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?

Authors:  Henry Völzke
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 4.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

5.  Central effects of humanin on hepatic triglyceride secretion.

Authors:  Zhenwei Gong; Kai Su; Lingguang Cui; Emir Tas; Ting Zhang; H Henry Dong; Shoshana Yakar; Radhika H Muzumdar
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-09       Impact factor: 4.310

6.  Alcoholic Liver Disease Is Associated with an Increased Risk of Gastric Cancer.

Authors:  Tae Hoon Ha; Byeong Gwan Kim; Donghyong Jeong; Sohee Oh; Won Kim; Yong Jin Jung; Dong Won Ahn; Ji Bong Jeong; Ji Won Kim; Kook Lae Lee; Seong-Joon Koh
Journal:  Dig Dis Sci       Date:  2016-10-26       Impact factor: 3.199

Review 7.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

Review 8.  Should nonalcoholic fatty liver disease be regarded as a hepatic illness only?

Authors:  Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

Review 9.  NAFLD, NASH and liver cancer.

Authors:  Gregory A Michelotti; Mariana V Machado; Anna Mae Diehl
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-01       Impact factor: 46.802

10.  Managing the Burden of Non-NASH NAFLD.

Authors:  Christopher J Danford; Jorge E Sanchez; Kathleen E Corey
Journal:  Curr Hepatol Rep       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.